LEO Pharma Hires Novo Nordisk Obesity Executive Ahead of Its IPO

LEO Pharma A/Shas poached a top Novo Nordisk A/S obesity executive as the closely held Danish drug company moves closer to an initial public offering.

Frederik Kier, currently senior vice president at Novo’s global obesity unit, will join LEO as of June 1, according to a statement on Tuesday. Kier will be in charge of international operations at the pharmaceutical company, which mostly focuses on skin conditions.

LEO, one of Denmark’s oldest drugmakers, has set a 2026 target for an IPO and earlier this year signed a $1.7 billion partnership deal on inflammatory diseases with Gilead Sciences Inc. ...